NEW YORK – Uppsala, Sweden-based diagnostics firm Gradientech announced Friday that it has signed an exclusive distribution agreement with IVD developer and supplier Biomedica. The agreement covers commercialization of the Gradientech QuickMIC system in Austria, Switzerland, and Central Eastern Europe. Financial terms were not disclosed.
The QuickMIC system uses antibiotic-embedded agarose gels and automated microscopy to determine minimum inhibitory concentrations from a positive blood culture in about two hours. Gradientech obtained the CE mark for its system and a Gram-negative bacterial panel in May.
Peter Karlberg, VP of sales at Gradientech, noted in a statement that Biomedica has "a complementary product portfolio for sepsis and the significant expertise needed to make the QuickMIC system a market leader for ultra-rapid antibiotic susceptibility testing at their markets."